Other major players, which include AstraZeneca, Pfizer, Sanofi, Roche, Amgen, and Boehringer Ingelheim, are expanding pipelines via innovation, acquisitions, and partnerships
For a deeper read on some of the above, wed recommend referring to this recent BMJ article on the topic
Fluid intake drops without conscious awareness
Semaglutide may be safe for many MS patients, but requires neurologist approval before starting
No active IND (Investigational New Drug application) is publicly listed in the United States as of 2025
[8] Overall, these side effects are short-lived and manageable, often improving by slowing the rate of administration or taking breaks during an intravenous infusion if needed